Celularity Inc. (NASDAQ: CELU) announced the publication of Phase 2 clinical trial results for its placenta-derived cell therapy PDA-002 in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE